#EQT #None #Qiming Venture Partners #Pulnovo Medical

EQT's Investment Fuels Pulnovo Medical's Expansion

Pulnovo Medical, a leader in medical devices for pulmonary hypertension (PH) and heart failure (HF), has recently welcomed EQT Group as a new investor. This partnership, alongside ongoing support from Qiming Venture Partners, comes after Pulnovo Medical's significant achievement of obtaining CE-MDR certification in Europe. The new investment heralds a pivotal moment in Pulnovo’s journey to broaden its international presence and enhance treatment options for those suffering from pulmonary hypertension worldwide.

For nearly a decade, Pulnovo Medical has been at the forefront of addressing cardiology’s most pressing challenges, particularly the complexities surrounding PH and HF. The introduction of the Pulmonary Artery Denervation (PADN) technology has been a game-changer, providing an innovative solution with robust clinical backing. The company has garnered numerous accolades, including the FDA Breakthrough Device designation in 2021, and has also received humanitarian use approval in 2023 from the FDA, highlighting its commitment to improving patient outcomes.

The recent investment from EQT Group indicates a growing confidence in Pulnovo Medical's mission. This financial influx will aid the company in scaling up international clinical trials, facilitating regulatory approvals in various territories, and pursuing commercial opportunities abroad. According to Zoe Zhu, Director on the EQT Private Capital Asia advisory team, the clinical landscape holds considerable unmet needs for patients with pulmonary hypertension and heart failure. She emphasized that Pulnovo's PADN solution shows promise in addressing these needs, asserting strong clinical evidence for improved outcomes.

Pulnovo Medical’s Chairwoman, Cynthia Chen, expressed gratitude to both EQT and Qiming Venture Partners for their trust and collaboration. She elaborated on the company’s commitment to meeting unmet clinical needs through original, scalable, and evidence-based innovations rooted in frontline care practices. “Transforming clinically driven innovation into global standards is challenging, but we are dedicated to providing meaningful medical value to patients around the world,” stated Chen.

The significance of CE-MDR certification cannot be overstated. Achieving this milestone marks a key strategic step toward global commercialization of their products, allowing for broader access to their technologies by healthcare providers and patients alike. Following this approval, the company will focus on executing strategies that promote more extensive clinical trial engagements and securing additional regulatory validations across international markets.

The support from EQT will not only bolster Pulnovo’s operational capabilities but also augment its strategic positioning within the competitive landscape of medical devices. As the landscape of treatment for chronic cardiovascular conditions evolves, Pulnovo aims to strengthen its foothold and continue delivering innovative solutions that enhance patient quality of life.

As it moves forward, Pulnovo Medical aims to harness EQT's extensive network and expertise within the healthcare and life sciences sectors to optimize their ongoing projects and reach new heights in their mission. By integrating advanced technology with patient-centric care, Pulnovo Medical plans to reshape the management of pulmonary hypertension on a global scale, truly making a difference in the lives of those affected.

In conclusion, the collaboration between Pulnovo Medical, EQT, and Qiming Venture Partners stands to create robust pathways for advancements in therapeutic methodologies, significantly impacting healthcare delivery for patients with pulmonary hypertension and heart failure across the globe.